Friday - May 16, 2025

LOGIN  |  REGISTER
Chimerix
C4 Therapeutics

Option Care Health To Participate In Upcoming Investor Conferences

November 07, 2023 | Last Trade: US$32.49 0.70 2.20

BANNOCKBURN, Ill., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, will participate in the following upcoming investor conferences:

  • Jefferies London Healthcare Conference, being held in London, on Tuesday, November 14, 2023, including a fireside chat at 10:30am GMT/5:30am ET.
  • Bank of America Leveraged Finance Conference, being held in Boca Raton, FL, on Tuesday, November 28, 2023, including a presentation at 2:50pm ET.
  • Bank of America Home Care Conference, being held virtually, on Monday, December 4, 2023, including a fireside chat at 9:10am ET.

Webcast links and related presentation materials will be available online at https://investors.optioncarehealth.com.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.

For Investor Inquiries:

Mike Shapiro, Chief Financial Officer
Option Care Health
312.940.2538
Investor.relations@optioncare.com

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page